Vermillion Company Profile (NASDAQ:VRML)

About Vermillion

Vermillion logoVermillion, Inc. is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. It sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. It developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated. Its ASPiRA LABS is a laboratory that provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Diagnostic Substances
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VRML
  • CUSIP:
Key Metrics:
  • Previous Close: $1.29
  • 50 Day Moving Average: $1.25
  • 200 Day Moving Average: $1.32
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $65.80M
  • Outstanding Shares: 52,222,000
  • Beta: 1.39
Additional Links:
Companies Related to Vermillion:

Analyst Ratings

Consensus Ratings for Vermillion (NASDAQ:VRML) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.50 (98.41% upside)

Analysts' Ratings History for Vermillion (NASDAQ:VRML)
DateFirmActionRatingPrice TargetDetails
5/18/2016Canaccord GenuityReiterated RatingBuyView Rating Details
8/17/2015Roth CapitalReiterated RatingBuyView Rating Details
(Data available from 8/25/2014 forward)


Earnings History for Vermillion (NASDAQ:VRML)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/10/2016Q216($0.09)($0.07)ViewListenView Earnings Details
5/16/2016Q116($0.09)($0.09)ViewListenView Earnings Details
3/24/2016Q415($0.10)$1.20 millionViewListenView Earnings Details
11/12/2015Q315($0.10)($0.10)ViewListenView Earnings Details
8/13/2015Q215($0.08)($0.11)$1.50 million$535.00 millionViewListenView Earnings Details
5/11/2015Q115($0.10)($0.10)ViewListenView Earnings Details
3/25/2015Q414($0.08)($0.11)$1.59 million$1.57 millionViewListenView Earnings Details
11/14/2013Q3($0.10)$319.00 million$330.00 millionViewListenView Earnings Details
8/14/2013Q2 2013($0.11)$0.32 million$0.23 millionViewListenView Earnings Details
5/15/2013Q1 2013($0.15)($0.17)$0.30 million$0.33 millionViewListenView Earnings Details
11/12/2012Q312($0.21)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Vermillion (NASDAQ:VRML)
No earnings estimates for this company have been tracked by


Dividend History for Vermillion (NASDAQ:VRML)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Vermillion (NASDAQ:VRML)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/28/2016Jack W SchulerMajor ShareholderBuy1,493$1.60$2,388.80View SEC Filing  
1/25/2016Jack W SchulerMajor ShareholderBuy3,700$1.57$5,809.00View SEC Filing  
1/21/2016Jack W SchulerMajor ShareholderBuy30,700$1.46$44,822.00View SEC Filing  
1/19/2016Jack W SchulerMajor ShareholderBuy57,749$1.45$83,736.05View SEC Filing  
1/15/2016Jack W SchulerMajor ShareholderBuy8,400$1.56$13,104.00View SEC Filing  
7/14/2015Larry N FeinbergInsiderBuy512,043$1.96$1,003,604.28View SEC Filing  
12/23/2014Jack W SchulerMajor ShareholderBuy1,288,339$1.44$1,855,208.16View SEC Filing  
12/23/2014Larry N FeinbergInsiderBuy972,222$1.44$1,399,999.68View SEC Filing  
12/19/2014Peter S RoddyDirectorBuy16,502$1.44$23,762.88View SEC Filing  
11/21/2014Valerie Barber PalmieriCOOBuy3,500$1.51$5,285.00View SEC Filing  
11/20/2014James T LafranceInsiderBuy27,907$1.44$40,186.08View SEC Filing  
11/20/2014Valerie Barber PalmieriCOOBuy30,000$1.44$43,200.00View SEC Filing  
11/19/2014James T LafranceInsiderBuy41,615$1.43$59,509.45View SEC Filing  
11/18/2014Eric SchoenCAOBuy5,000$1.42$7,100.00View SEC Filing  
11/20/2013William B CreechVPBuy2,000$2.33$4,660.00View SEC Filing  
6/11/2013William B CreechVPBuy10,000$3.18$31,800.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Vermillion (NASDAQ:VRML)
DateHeadline logoETF’s with exposure to Vermillion, Inc. : August 16, 2016 (NASDAQ:VRML) - August 16 at 8:14 PM logoVermillion, Inc. :VRML-US: Earnings Analysis: Q2, 2016 By the Numbers : August 12, 2016 (NASDAQ:VRML) - August 12 at 11:29 AM logoVermillion Reports Second Quarter 2016 Results (NASDAQ:VRML) - August 10 at 8:51 PM logoVermillion reports 2Q loss (NASDAQ:VRML) - August 10 at 11:25 AM logoVERMILLION, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:VRML) - August 10 at 11:25 AM logoVermillion to Present Corporate Overview at the Canaccord Genuity 36th Annual Growth Conference (NASDAQ:VRML) - August 8 at 8:22 PM logoASPiRA LABS Expands Coverage for OVA1® in California (NASDAQ:VRML) - August 2 at 8:35 PM logoVermillion to Report Second Quarter 2016 Financial Results and Host Investor Conference Call on August 10th (NASDAQ:VRML) - July 29 at 9:00 AM logoASPiRA LABS Expands Coverage for OVA1 in Texas (NASDAQ:VRML) - July 27 at 9:48 AM logoASPiRA LABS Announces Strategic Michigan Coverage for OVA1 (NASDAQ:VRML) - July 19 at 9:15 AM logoETF’s with exposure to Vermillion, Inc. : July 18, 2016 (NASDAQ:VRML) - July 18 at 2:29 PM logoVERMILLION, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NASDAQ:VRML) - June 22 at 4:07 PM logoCroatia Launches Oil Exploration with 5 Blocks, $75M Investment (NASDAQ:VRML) - June 10 at 2:23 PM logoETF’s with exposure to Vermillion, Inc. : June 7, 2016 (NASDAQ:VRML) - June 7 at 5:49 PM logoVermillion, Inc. :VRML-US: Earnings Analysis: Q1, 2016 By the Numbers : June 3, 2016 (NASDAQ:VRML) - June 3 at 11:04 AM logoVermillion Teams up With NASCAR Driver Martin Truex, Jr. and Partner Sherry Pollex, an Ovarian Cancer Thriver, to "Accelerate" the National Conversation about Ovarian Cancer and OVA1® (NASDAQ:VRML) - February 16 at 9:00 AM logoVERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Other Events (NASDAQ:VRML) - February 12 at 4:07 PM logoVermillion's CPRIT-Sponsored Pelvic Mass Registry Steering Committee Chartered (NASDAQ:VRML) - February 11 at 9:00 AM logoVermillion Lands America's Most Decorated Gymnast and Ovarian Cancer Survivor, Shannon Miller, for its OVA1® Awareness Team (NASDAQ:VRML) - February 9 at 9:00 AM
News IconLatest Analysts Reports On Vermillion, Inc. (VRML) - Risers & Fallers (NASDAQ:VRML) - February 1 at 2:36 PM
News IconA Major Shareholder at Vermillion (NASDAQ: VRML) is Buying Shares - Analyst Ratings (NASDAQ:VRML) - January 21 at 1:40 PM
News IconAnalyst Coverage Updates - Vermillion, Inc. (VRML) - Risers & Fallers (NASDAQ:VRML) - January 20 at 1:26 PM logoVermillion to Present at 7th Annual Life Science CEO Forum - CNNMoney (NASDAQ:VRML) - January 19 at 12:58 PM logoVermillion to Present at 7th Annual Life Science CEO Forum (NASDAQ:VRML) - January 19 at 11:05 AM logoVermillion Exits 2015 with 33M Lives Covered for OVA1® (NASDAQ:VRML) - January 11 at 11:28 AM logoVERMILLION, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:VRML) - January 11 at 6:54 AM logoVERMILLION, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:VRML) - January 4 at 4:14 PM logoVermillion to Host Key Opinion Leader Meeting to Discuss Advances in Ovarian Cancer Detection (NASDAQ:VRML) - December 9 at 3:05 PM logoVERMILLION, INC. Financials (NASDAQ:VRML) - December 8 at 1:17 PM logoVermillion Announces Key Medical Policy Coverage by Medi-Cal for OVA1® Test (NASDAQ:VRML) - December 1 at 11:18 AM logoVermillion to Present Corporate Overview at the Canaccord Genuity Medical Technology & Diagnostics Forum (NASDAQ:VRML) - November 17 at 10:33 AM logoVermillion Reports Third Quarter 2015 Financial Results and Business Update (NASDAQ:VRML) - November 12 at 9:56 AM


Vermillion (NASDAQ:VRML) Chart for Thursday, August, 25, 2016

Last Updated on 8/25/2016 by Staff